Log in to your Inderes Free account to see all free content on this page.
Camurus
670.00 SEK
-3.04 %
Less than 1K followers
CAMX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-3.04 %
+0.75 %
+8.77 %
+7.29 %
+4.52 %
+12.32 %
+159.69 %
+225.24 %
+1,008.80 %
Camurus operates in biotechnology. The company is operated as a research-based pharmaceutical company that develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders and patients with opioid addiction. Camurus runs development projects under its own management and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Read moreMarket cap
40.12B SEK
Turnover
97.03M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12.2.
2026
Annual report '25
12.5.
2026
Interim report Q1'26
28.5.
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
Camurus, Audiocast, Q4'25
Camurus AB: Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
